Adaptive Symptom Self-Management Immunotherapy Study
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Arizona
About this trial
The use of immune checkpoint inhibitors (ICIs), alone or in combination with other cancer treatments is increasing dramatically with immune-related adverse events (irAEs) common (90%) during ICI treatment. Most irAEs are symptomatic and symptom self-management with timely reporting of moderate or severe symptoms to health care providers (HCPs) may reduce irAE severity by early recognition and management, resulting in fewer treatment interruptions and unscheduled health services.
Eligibility criteria
Qualifiers
Age 18 or older
Within 12 weeks after starting ICI treatment for cancer
Cognitively oriented to person, place and time (determined by recruiter)
Able to speak and understand English or Spanish
Disqualifiers
Currently receiving regular behavioral counseling
Trial design
Treatments tested in this trial
- Automated Telephone Symptom Management (ATMS) and Telephone Interpersonal Counseling (TIP-C)
- Active control comparator
Treatment groups
400 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Arizona
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov